Entasis Therapeutics

-$0.00 (-0.23%) Today

-$0.00 (-0.23%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ETTX and other ETFs, options, and stocks.

About ETTX

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections.

CEO

Manoussos Perros

Employees

Headquarters

Waltham, Massachusetts

Founded

2015

ETTX Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

873.60K

High today

$2.19

Low today

$2.18

Open price

$2.18

Volume

116.70K

52 Week high

$3.88

52 Week low

$1.40

ETTX News

BenzingaMay 23

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approxim

MarketWatchMay 23

Innoviva to Buy Rest of Entasis for $2.20 a Share in Cash - MarketWatch

By Michael Dabaie Innoviva Inc. agreed to acquire all the shares of late-stage clinical biopharmaceutical company Entasis Therapeutics Holdings Inc. it doesn't

ETTX Earnings

-$0.37

-$0.25

-$0.12

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 10, After Hours

Why Robinhood?

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. View more

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva to Buy Rest of Entasis for $2.20 a Share in Cash - MarketWatch

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections.